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Loss of Class III b-Tubulin Induced by Histone
Deacetylation Is Associated with Chemosensitivity to
Paclitaxel in Malignant Melanoma Cells
Kiyomi Akasaka1,2, Chihaya Maesawa1, Masahiko Shibazaki1, Fumihiko Maeda2, Kazuhiro Takahashi2,
Toshihide Akasaka2 and Tomoyuki Masuda1
Overexpression of class III b-tubulin (TUBB3) is an important mechanism of taxane resistance. Using 7
melanoma cell lines, 2 normal neonatal human epidermal melanocyte (NHEM) cultures, and 49 primary
melanomas, we investigated TUBB3 expression, its relationship to chemosensitivity to taxane derivatives, and
the epigenetic mechanism controlling TUBB3 gene expression. Normal melanocytes in vitro and in vivo strongly
expressed TUBB3 protein. NHEMs exhibited marked chemoresistance to paclitaxel-induced apoptosis. A subset
(10 of 49, 20%) of primary malignant melanomas was TUBB3 negative. The incidence of TUBB3-negative
melanomas increased with stage of progression. TUBB3 protein expression varied among cell lines; one (HMV-I)
of the seven cell lines exhibited an extremely low endogenous level. TUBB3 protein expression correlated well
with chemosensitivity to paclitaxel-induced apoptosis (Po0.05). Treatment with a histone deacetylase (HDAC)
inhibitor restored TUBB3 expression in HMV-I. Chromatin immunoprecipitation assays revealed that histones
H3 and H4 were hypoacetylated at the TUBB3 gene in HMV-I as compared with a TUBB3-overexpressing cell
type (HMV-II). Treatment with the HDAC inhibitor induced gain of histone acetylation only in HMV-I. These
results suggest that loss of TUBB3 protein may be induced by histone deacetylation in a subset of malignant
melanomas, and may be associated with chemosensitivity to taxane.
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INTRODUCTION
Malignant melanoma represents less than 10% of skin cancer
cases, but accounts for 80% of skin cancer deaths (Ives et al.,
2007). The primary treatment for locoregional disease is
surgical excision, and is curative in a large proportion of
patients with early-stage melanoma. However, 10–40% of
patients with TNM stages I and II disease and 40–80% of
patients with stage III disease die of metastatic disease within
5 years of the initial diagnosis (Balch et al., 2001). The
prognosis for patients with metastatic melanoma is poor.
Chemotherapy with dacarbazine is presently the standard
treatment regimen in metastasized melanoma, with reported
response rates of only 10–18% (Therasse et al., 2000).
However, recent studies suggest much lower response rates
of 6–7% (Schadendorf et al., 2006). Although biochemother-
apy and immunotherapy regimens have also been used, they
have not proven to be superior to dacarbazine-based
chemotherapy (Eigentler et al., 2003).
Taxane-based regimens are considered as second-line
chemotherapy for metastatic melanoma, and some clinical
trials have been performed (Legha et al., 1990; Hodi et al.,
2002; Gogas et al., 2004; Rao et al., 2006; Ugurel et al.,
2006). Higher response rates (12–41%) were seen in these
reports when taxanes were given in association with other
anticancer agents, such as temozolomide, dacarbazine,
cisplatin, carboplatin, or tamoxifen (Mohith et al., 1996;
Nathan et al., 2000; Hodi et al., 2002; Bafaloukos et al.,
2002a, b; Tas et al., 2003; Rao et al., 2006; Ugurel et al.,
2006). However, there have been some pessimistic reports on
the efficacy of taxane derivatives; the response rate of single-
agent therapy appears quite low (Legha et al., 1990; Walker
et al., 2005) and there were no differences in median survival
time and median time to progression between paclitaxel with
and without carboplatin (Zimpfer-Rechner et al., 2003). The
efficacy of taxane derivatives is thus controversial in
malignant melanomas and at best is limited to a subset of
patients.
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Resistance to chemotherapy is due in part to the intrinsic
and/or extrinsic insensitivity of tumor cells to systemic
treatment with antineoplastic agents. In the case of resistance
to taxane derivatives, in vitro and in vivo studies have
suggested that overexpression of particular b-tubulin isotypes
is involved in taxane resistance (Derry et al., 1997; Kavallaris
et al., 1997; Mozzetti et al., 2005; Seve et al., 2005). Six
b-tubulin isotypes have been identified in mammalian cells,
encoded by different genes and with distinct patterns of tissue
expression (Luduena, 1998). The class III b-tubulin, TUBB3,
is a well-known neuronal tubulin that is expressed in the
earliest phase of neural differentiation and is neuron
associated (Luduena, 1998). TUBB3 has been suggested to
counteract the suppression of microtubule dynamicity by
paclitaxel by enhancement of microtubule instability or,
alternatively, by reduction of microtubule polymerization
rate (Derry et al., 1997; Kavallaris et al., 1997; Mozzetti et al.,
2005; Seve et al., 2005). Recently, Mhaidat et al. (2008)
demonstrated that sensitivity to docetaxel-induced apoptosis
correlates with TUBB3 protein expression in malignant
melanoma cell lines. Hence, they suggested that over-
expression of TUBB3 protein might help identify patients
with melanoma who will respond to taxane derivatives
(Mhaidat et al., 2008). However, TUBB3 expression has
never been systematically examined in malignant melanomas
and normal melanocytes. Moreover, the molecular mechan-
isms of TUBB3 protein overexpression have not been fully
elucidated in these cell types. We have recently demon-
strated that epigenetic modifications (DNA methylation and
histone acetylation) are associated with aberrant TUBB3
protein expression in ovarian cancer cells (Izutsu et al.,
2008).
In this study, we show that human normal epidermal
melanocytes and most primary malignant melanomas are
TUBB3 positive, and that loss of TUBB3 protein induced by
histone deacetylation correlates with chemosensitivity to
paclitaxel in malignant melanoma cells.
RESULTS
Immunohistochemistry of TUBB3 protein and relationship
between expression and clinicopathological variables
We immunohistochemically examined TUBB3 protein
expression in 49 patients with malignant melanoma and 10
with nonneoplastic skin disease. Dense immunoreactivity for
TUBB3 protein was observed in normal epidermal melano-
cytes (Figure 1a) and nerve cells in nonneoplastic lesions
obtained from all samples. TUBB3 protein was localized in
the cytoplasm (Figure 1a). Immunoreactivity for TUBB3
protein varied among primary malignant melanomas (Figure
1b–d), and intratumoral heterogeneity was frequently
observed. Two independent pathologists performed quanti-
tative assessment of immunohistochemical staining. Positive
immunoreactivity was observed in 39 (80%) of the 49 cases
(medium, 11; strong, 28). Of the 49, 10 (20%) primary
malignant melanomas were TUBB3 negative. Table 1 sum-
marizes the relationship between TUBB3 immunoreactivity
and clinicopathological variables of all cases. Although there
was a trend for high-stage tumors to exhibit loss of TUBB3
protein expression, the differences were not statistically
significant (Table 1). TUBB3 protein disappeared in one case
Figure 1. Immunohistochemistry for TUBB3 protein in melanocytes from patients with benign disease and in malignant melanomas. (a) Positive
immunoreactivity for TUBB3 protein is observed in normal epidermal melanocytes in a patient with bone fracture. TUBB3 immunoreactivity is observed in
melanocytes scattered in the basal layer of the epidermis. (b–d) TUBB3 immunoreactivity in primary malignant melanomas. Quantitative comparative analysis
(proportion and intensity scores) was performed on immunohistochemical staining of TUBB3 protein (Materials and Methods). Assessments of three cases are
represented (b, negative; c, medium; d, strong). Bar¼ 100mm.
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of malignant melanoma in situ (1 of 5, 20%; Table 1). These
data indicate that loss of TUBB3 protein expression occurs in
a subset of malignant melanomas, and that such loss is more
frequent as the tumor progresses.
We further examined the relationship between TUBB3
immunoreactivity and disease outcome in 38 patients with
stages II–IV disease (excluding patients with stage 0/I). A total
of 9 patients were TUBB3 negative and 29 were TUBB3
positive. Follow-up data were available for all patients. After
a median follow-up of 45 months (range, 2–123 months), 15
patients (39%) had died of disease relapse. Kaplan–Meier
curves showed a trend towards worse outcome in patients
with TUBB3-negative immunoreactivity compared with
patients with TUBB3-positive immunoreactivity, although
the difference was not statistically significant (P¼0.061,
log-rank test; Figure 2).
Relationship between TUBB3 protein expression and
chemosensitivity to paclitaxel in melanoma cell lines and
normal melanocyte cells
We investigated TUBB3 protein expression in 7 human
melanoma cell lines (HMV-I, HMV-II, MM-RU, SK-MEL-28,
PM-WK, CRL1579, and G361) and 2 primary cultures of
neonatal human epidermal melanocytes (NHEM-M and
NHEM-D). The two normal NHEM cultures strongly
expressed TUBB3 protein, whereas expression in malignant
melanoma cell lines varied (Figure 3a), a result compatible
with the immunohistochemical studies in primary malignant
melanomas and normal epidermal melanocytes. Six
melanoma cell lines exhibited dense signals (HMV-II, MM-
RU, SK-MEL-28, PM-WK, CRL1579, and G-361) and one
(HMV-I) showed a relatively weak signal. As overexpression
of TUBB3 protein is known to be associated with reduced
chemosensitivity to paclitaxel in diverse human malignan-
cies, we carried out cell viability assays in cultured cells.
Dose- and time-dependent cell viability curves showed that
the two NHEMs, which strongly expressed TUBB3
protein, were markedly resistant to paclitaxel cytotoxicity
(Figure 3c and d), and the amount of TUBB3 protein
correlated well with chemosensitivity (rs¼ 0.328, Po0.05;
Figure 3e). Chemosensitivity data evaluated by the adenosine
triphosphate (ATP) assay for each cell line are represented in
Figure S1. Interestingly, the two melanoma cell lines HMV-I
and HMV-II, which originated from the same patient and had
differentiated as subclones (Naoi et al., 1988), exhibited
differences in TUBB3 protein expression (Figure 3a), and
chemosensitivity to paclitaxel (Figure 3c and d). The mRNA/
protein expression profiles of both cell lines are summarized
in Figure S2.
Apoptotic assays (DNA fragmentation and flow cytome-
trical analyses) represented that a high level of paclitaxel-
induced apoptotic cells was observed in the TUBB3-negative
melanoma cell line (HMV-I) in contrast to TUBB3-expressing
cell types (HMV-II and NHEM-D) (Figure S3). The incidence
Table 1. Correlation between TUBB3 immunoreactivity
and clinicopathological variables in 49 patients with
malignant melanomas
TUBB3 immunoreactivity
Characteristics n
Positive
(%)
Negative
(%) P-value1
Tumor location
Head and
neck
6 3 (50) 3 (50) 0.20
Trunk 5 5 (100) 0 (0)
Extremities 3 3 (100) 0 (0)
Acral 35 28 (80) 7 (20)
Type
SSM 6 5 (83) 1 (17) 0.16
LMM 2 1 (50) 1 (50)
NM 6 5 (83) 1 (17)
ALM 35 28 (80) 7 (20)
Tumor thickness
(mm)
p1.0 9 8 (89) 1 (11) 0.67
1.01–2.0 12 10 (83) 2 (17)
2.01–4.0 13 10 (77) 3 (23)
X4.0 15 11 (73) 4 (27)
Clinical stage2
0 5 4 (80) 1 (20) 0.40
I 6 6 (100) 0 (0)
II 20 16 (80) 4 (20)
III 15 11 (73) 4 (27)
IV 3 2 (67) 1 (33)
ALM, acral lentiginous melanoma; LMM, lentigo maligna melanoma;
NM, nodular melanoma; SSM, superficial spreading melanoma; TUBB3,
class III b-tubulin.
1P-value from Kruskal–Wallis test.
2Clinical stage was defined according to the melanoma TNM classifica-
tion (Balch et al., 2001).
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Figure 2. Survival curves of 38 melanoma patients according to TUBB3
immunoreactivity. Kaplan–Meier estimates of survival among 38 patients with
malignant melanomas with (n¼29) and without (n¼ 9) TUBB3
immunoreactivity (stages II–IV). Patients with TUBB3 loss show a trend
towards worse prognosis, without statistical significance (log-rank test,
P¼ 0.061).
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of apoptotic cells was intermediate in a cell line that was
weakly TUBB3 poistive (PM-WK; Figure S3).
We also confirmed that paclitaxel treatment induced the
cleavage of polyadenosine diphosphate-ribose polymerase
and caspase-3 activation in HMV-I and PM-WK, which were
negative and weakly TUBB3-expressing cell types, respec-
tively (Figure S4).
Silencing of TUBB3 increases chemosensitivity to paclitaxel in
melanoma cells
To investigate whether knockdown of TUBB3 expression
increases chemosensitivity to paclitaxel, we used the small-
interfering RNA (siRNA) technique in a TUBB3-overexpressing
melanoma cell line (HMV-II). First, we generated three siRNA
duplexes (si-761, si-1004, and si-1475) and transfected them into
HMV-II. In comparison with a negative control (negative
universal control), all siRNAs decreased TUBB3 protein expres-
sion to various extents at day 3 after transfection (Figure 4a).
si-1475 was able to repress TUBB3 protein expression below
10% of that in the negative control (Figure 4a) and to decrease
TUBB3 mRNA expression by about 70–80% throughout the
experimental period (3 days) as assessed by real-time reverse
transcriptase-PCR (Figure 4b). We then performed cell viability
tests with the si-1475 siRNA duplex. Chemosensitivity to
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Figure 3. Results of western blot for TUBB3 protein expression and chemosensitivity to paclitaxel in seven melanoma cell lines and two primary cultures of
NHEMs. (a) Western blot for TUBB3 protein in seven melanoma cell lines and two primary cultures of NHEMs. MM, malignant melanoma. NM, normal
melanocyte. (b) Quantitative results of western blot for TUBB3 protein in seven melanoma cell lines and two primary cultures of NHEMs. (c) Cells were treated
with various doses of paclitaxel (0, 10, 20, 40, and 80nM) for 72 hours. Percentage viability was determined by the ATP assay. (d) Time-dependent cytotoxic
effects evaluated by ATP assay. Cells were treated with paclitaxel (40 nM) for 24, 48, and 72 hours. (e) Correlation between relative expression of TUBB3 protein
and chemosensitivity. Significant correlation was observed between them (Spearman’s correlation coefficient by rank test, rs¼ 0.328, Po0.05).
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incubation with 20 and 80nM of paclitaxel for 3 days was
significantly increased by treatment with si-1475.
Thus, loss of TUBB3 protein expression appears to occur
in a subset (o20%) of malignant melanomas in vitro and
in vivo, and might be associated with gain of chemo-
sensitivity to paclitaxel. We further examined the molecular
mechanism controlling TUBB3 protein expression in malig-
nant melanomas.
Treatment with a demethylating agent or a histone deacetylase
inhibitor
We have recently reported that epigenetic modifications
(DNA methylation and histone acetylation) are key mechan-
isms controlling aberrant TUBB3 protein expression in
ovarian cancer cells (Izutsu et al., 2008). Consequently, we
treated seven melanoma cell lines and two NHEM
cultures with a demethylating agent (5-aza-20-deoxycytidine,
5-Aza-dC, 3 mM) or a histone deacetylase (HDAC) inhibitor
(4-phenylbutyric acid, PBA, 3mM).
The PBA treatment markedly induced protein expression
in a TUBB3-negative melanoma cell line (HMV-I). A slight
increase was observed after 5-Aza-dC treatment, but it was
less than after PBA treatment (Figure 5). Expression of mRNA
was compatible with that of protein expression (Figure 5b).
This observation suggests that the loss of TUBB3 protein
expression might involve modulation of histone acetylation,
as previously described (Izutsu et al., 2008).
We also examined whether PBA treatment affects chemo-
sensitivity to paclitaxel in melanoma cell lines. Pretreatment
with PBA reduced the cytotoxicity of paclitaxel in two cell
lines which were negative and weakly TUBB3-expressing cell
types, respectively (HMV-I and PM-WK), whereas no
significant effects were observed in two strongly TUBB3-
positive (HMV-II and CRL1579) cell lines (Figure S5).
ChIP assay
To assess whether chromatin modifications at the CpG island
of the TUBB3 gene within intron 1 are associated with
mRNA/protein expression, we performed chromatin immu-
noprecipitation (ChIP) experiments with antibodies against
acetylated histone proteins and HDAC1 (Figure 6). This
location represents the binding site of the zinc-finger gene-
specific repressor element-1 silencing transcription factor/
neuronal restricted silencing factor (REST/NRSF), and we
have identified this location as an important site for
epigenetic modification of the TUBB3 gene in ovarian
cancers (Izutsu et al., 2008). Before PBA treatment, the
acetylation status of histones H3 and H4 in HMV-I was
inferior to that of HMV-II, and the inverse was observed for
HDAC1. Treatment with PBA increased histone H3 and H4
acetylation in HMV-I. The ChIP result for HDAC1 was
inversely correlated with the histone acetylation status of the
TUBB3 gene. In HMV-II, PBA treatment did not cause any
marked changes in the ChIP assays.
DISCUSSION
There has been no previous report that normal human
epidermal melanocytes are robustly TUBB3 positive in vitro
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Figure 4. siRNA targeting of TUBB3 specifically inhibits its expression and
chemosensitivity to paclitaxel in a TUBB3-overexpressing melanoma cell
line. (a) HMV-II cells were transfected (600 pmol) with control siRNA (NC) or
TUBB3-specific siRNAs and whole cell lysates were subjected to western blot
analysis for TUBB3 protein. Relative expression of TUBB3 protein was most
repressed in si-1475-transfected samples. (b) Analysis of TUBB3 gene
expression by RT–PCR after days 1–3 of siRNA transfection at 600 pmol.
Quantitative results of TUBB3 mRNA are compatible with those of protein
expression. (c) HMV-II cells treated with control siRNA (NC) and si-1475-
transfected cells (600 pmol) were subjected to the indicated dose titration of
paclitaxel (0, 10, 20, or 80 nM) for 3 days. Six samples were used in each
experiment, and three independent experiments were performed in each
concentration. Cell viability was significantly repressed in cells transfected
with si-1475 (Po0.05).
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and in vivo and that primary cultures are markedly
chemoresistant to paclitaxel. In addition, the immunohisto-
chemistry suggests that a subset of malignant melanomas lose
TUBB3 protein expression and that intratumor heterogeneity
of TUBB3 immunoreactivity is frequently observed in primary
malignant melanomas. Moreover, our in vitro studies support
previous reports that TUBB3 protein expression correlates
well with chemosensitivity to taxane derivatives (Derry et al.,
1997; Kavallaris et al., 1997; Mozzetti et al., 2005;
Seve et al., 2005; Mhaidat et al., 2008). Thus, these
observations reflect the low response rate of taxane single-
agent therapy in clinical studies (Legha et al., 1990; Walker
et al., 2005).
The appearance of melanocytes in the dermis takes place
in a craniocaudal direction, in accordance with the develop-
ment of neural crest from which melanocytes are derived.
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Figure 5. TUBB3 mRNA/protein expression in seven melanoma cell lines and two primary cultures of NHEMs treated with a demethylating agent
(A3, 3lM 5-Aza-dC) and a histone deacetylase inhibitor (P3, 3mM PBA). (a) Western bolt for TUBB3 protein expression with and without a demethylating agent
(A3, 3mM 5-Aza-dC) and a histone deacetylase inhibitor (P3, 3mM PBA). Gain of TUBB3 expression was observed in a melanoma cell line (HMV-I) that
had been TUBB3 negative, whereas expression in the remaining melanoma cell lines and 2 NHEMs was not markedly altered except PM-WK. NT, no
treatment control. (b) Results of real-time quantitative PCR for TUBB3 mRNA with and without a demethylating agent (A3, 3mM 5-Aza-dC) and a histone
deacetylase inhibitor (P3, 3mM PBA). Almost all data were compatible with protein expression.
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It is not surprising that normal melanocytes robustly express
TUBB3 protein. Our immunohistochemical study suggested a
trend for loss of TUBB3 expression to occur with progression
of tumor stage and to be related with poor prognosis,
although statistical significance was not observed for either
event. A poor disease outcome was linked to high TUBB3
expression levels in some cancer types, such as ovary and
lung (Mozzetti et al., 2005; Seve et al., 2005; Ferrandina
et al., 2006). In fact, the number of subjects in our study is
not enough to address the prognostic significance of TUBB3
loss in primary malignant melanomas. In addition,
previous reports on other types of cancers contradicted our
immunohistochemical study. However, normal counterparts
of these tumors do not basally express TUBB3 protein, and
microenvironmental conditions in these tumors, such as
hypoxia, induced aberrant TUBB3 expression (Raspaglio
et al., 2007). Hence, TUBB3 downregulation in melanoma
patients might be simply associated with a worse outcome, as
a marker of tumor progression, and dedifferentiation linked to
genetic and epigenetic alterations.
We are interested in the molecular mechanisms associated
with aberrant expression of neuron-specific genes and the
relationship of such expression to the behavior of tumor cells.
The association between chemosensitivity to taxane deriva-
tives and the expression of neuronal tubulin, TUBB3, is a
central issue. We have shown that aberrant TUBB3 expres-
sion is caused by epigenetic modifications (DNA methylation
and chromatin acetylation) in ovarian cancer (Izutsu et al.,
2008). Of these modifications, histone deacetylation at the
repressor element-1 site is important mechanism for gain of
TUBB3 protein expression. REST/NRSF is a transcription
factor that has been proposed to be important in establishing
and maintaining the expression of neuron-specific genes by
recruiting various chromatin-modifying enzymes such as
class I HDACs (HDAC1 and HDAC2), Sin3, G9a, and
CoREST (Ballas et al., 2005; Lunyak and Rosenfeld, 2005).
These factors cooperate and repress target gene expression by
epigenetic mechanisms in nonneuronal cell types. Expression
of class I neuronal genes is initiated by the dissociation of the
REST complex from the repressor element-1 binding site
(Ballas et al., 2005; Lunyak and Rosenfeld, 2005). Expression
of class II neuronal genes is induced by REST/NRSF-
independent deacetylation when a specific stimulus, such
as membrane depolarization, occurs in neurons (Ballas et al.,
2005; Lunyak and Rosenfeld, 2005). The details of the
epigenetic mechanisms associated with REST/NRSF have
never been examined in normal melanocytes and melano-
mas, and there has been no previous evidence that, like
neuronal cells, epidermal melanocytes and most melanoma
cells are robustly TUBB3 positive.
Histone deacetylation influences the expression of genes
involved in both cancer initiation and cancer progression
(Glozak and Seto, 2007; Xu et al., 2007). For instance,
hypoxia, such as encountered in the center of solid tumors,
enhances angiogenesis and also induces HDAC expression
and activity (Kim et al., 2001; Deroanne et al., 2002).
HDAC1 overexpression represses tumor suppressor genes,
such as p53 and the von Hippel-Lindau gene, associated with
angiogenesis (Kim et al., 2001; Deroanne et al., 2002).
Expression of metastasis-related proteins, such as E-cadherin,
is also linked to HDAC activity (Peinado et al., 2004). The
repressor Snail recruits HDAC1 and HDAC2 and the
corepressor Sin3A to the E-cadherin promoter, resulting in
repression of E-cadherin mRNA. Snail overexpression corre-
lates with an increase in hypoacetylation of histones H3 and
H4. Thus, hypoacetylation at specific genes frequently occurs
with microenvironmental change (such as hypoxia) and/or
tumor progression. Moreover, Fraga et al. (2005) demon-
strated that cancer cells have a global loss of monoacetylated
and trimethylated forms of histone H4 as compared with their
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Figure 6. ChIP assay in melanoma cell lines. ChIP assays for acetylated
histones (a) H3 (H3-ac), (b) H4 (H4-ac), and (c) HDAC1 at the region of the
second CpG site. In HMV-I, acetylated H3 and H4 histones increased after
treatment with the HDAC inhibitor (P3, 3mM PBA) in comparison with the no-
treatment control. An inverse relationship to the results for the acetylated
histones was observed in the case of HDAC1. NT, no treatment control. No
significant differences in H3 and H4 histones and HDAC1 were observed
before and after treatment in HMV-II (a TUBB3-overexpressing cell type).
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normal counterparts (Fraga et al., 2005). In their mouse
model of multistage skin carcinogenesis, these changes
appeared early and accumulated during the tumorigenic
process (Fraga et al., 2005). These findings and those of our
in vitro acetylation study are compatible with the data by
Fraga et al. (2005). Global and site-specific hypoacetylation
may contribute to the development of biological behaviors
(including chemoresistance) in melanoma cells.
Our immunohistochemistry for TUBB3 protein expression
appears to be a good biomarker to select patients for
chemotherapy with taxane derivatives. Analogously, chemo-
sensitivity testing using an ATP bioluminescence assay has
been used to identify patients with malignant melanoma who
might benefit from chemotherapy with paclitaxel-based
regimens, resulting in a complete remission and a partial
response in seven patients treated (Ugurel et al., 2006).
Combination of TUBB3 immunohistochemistry with such
drug-sensitivity testing may provide useful information for
individualized chemotherapy of malignant melanoma in the
clinical setting. Conclusively, taxane-based regimens should
be taken into consideration only in patients with a low level
of TUBB3 protein.
MATERIALS AND METHODS
Cell lines and surgical specimens of malignant melanomas
Five human melanoma cell lines (HMV-I, HMV-II, SK-MEL-28,
CRL1579, and G361) and two primary cultures of NHEMs (NHEM-M
and NHEM-D) were obtained from the Cell Resource Center for
Biomedical Research, Tohoku University (Sendai, Japan) and
Cascade Biologics Inc. (Portland, OR), respectively. Two melanoma
cell lines (MM-RU and PM-WK) were donated by Professor MC
Mihm (Department of Dermatology, Harvard Medical School,
Boston, MA). All cell lines were maintained under the recommended
conditions.
Immunohistochemistry for TUBB3 protein expression was per-
formed in tumor samples from 49 patients with malignant melanoma
(including 5 patients with malignant melanoma in situ) treated
between 1997 and 2006 in the Department of Dermatology, School
of Medicine, Iwate Medical University, Morioka, Japan. Surgical
specimens were fixed in 10% buffered formalin solution and
embedded in paraffin wax, and two or more blocks were made for
immunohistochemistry. Permission for the study was obtained from
the Institutional Review Board (School of Medicine, Iwate Medical
University, Morioka, Japan) and written informed patient consent
(based on Helsinki Guidelines) was obtained from all patients before
surgery.
Reagents and antibodies
Paclitaxel (Calbiochem, Darmstadt, Germany) was prepared at a
stock concentration of 10mM in DMSO. For epigenetic studies, we
also prepared stock solutions of a demethylation agent (5-Aza-dC,
3M) and an HDAC inhibitor (PBA, 30mM) in DMSO.
For immunohistochemistry and immunofluorescence, a mouse
monoclonal anti-TUBB3 antibody (diluted 1:500 for immunohisto-
chemistry or 1:100 for immunofluorescence, respectively; Covance,
Princeton, NJ) and a rabbit polyclonal anticleaved caspase-3
antibody (diluted 1:200; Cell Signaling Technology, Danvers, MA)
were used. Secondary antibodies for immunofluorescence were
Alexa Fluor 594 conjugated anti-mouse or anti-rabbit IgG (diluted 1:
250; Invitrogen, Carlsbad, CA).
For western blot of TUBB3 protein, the same primary antibody
used for immunohistochemistry was used. Other primary antibodies
(a mouse monoclonal anti-class I b-tubulin antibody (Sigma
Chemical Co. Ltd, Saint Louis, MO), a rabbit polyclonal poly-
adenosine diphosphate-ribose polymerase antibody (diluted
1:1,000; Cell Signaling Technology) and a mouse monoclonal
antiglyceraldehyde-3-phosphate dehydrogenase antibody (GAPDH;
Upstate Biotech, Lake Placid, NY)) were also used for western blot.
Secondary antibodies used for Western blot were anti-mouse IgG or
anti-rabbit IgG (1:5,000; Amersham Biosciences, Piscataway, NJ).
To analyze expression of cleaved caspase-3 by flow cytometry,
we used the same primary antibody as used for immunofluorescence
and Zenon Alexa Fluor 488 Rabbit IgG Labeling Kit (Invitrogen).
For ChIP assay, anti-acetyl-histone-H3 and -H4 and anti-NRSF/
REST polyclonal antibodies were obtained from Upstate Biotech.
A monoclonal anti-HDAC1 antibody (clone 2E10; Upstate Biotech)
was also purchased.
For immunofluorescence, 40,6-diamino-2-phenylindole (diluted
1:1,000; Wako, Osaka, Japan) solution was used.
Immunohistochemistry
Sections 4mm thick were cut from formalin-fixed and paraffin-
embedded samples, and stained with hematoxylin and eosin. Serial
sections were stained with the avidin–biotin system and antigen
retrieval methods on a Ventana-automated immunostainer with the
Ventana immunohistochemistry detection system (Ventana Medical
Systems, Tucson, AZ), according to the manufacturer’s manual.
Quantitative comparative analysis of immunohistochemical staining
was carried out in each case. The extent of immunohistochemical
reactivity was estimated by light microscopy and graded according
to the number of immunoreactive cells (proportion score) and
staining intensity (intensity score). In brief, proportion scores were
graded as follows: 0, no immunoreactive cells were seen; 1, the
number of immunoreactive cells was less than 1%; 2, less than 10%;
3, less than one-third; 4, less than two-thirds; and 5, more than two-
thirds. Intensity scores were graded as follows: 0, there was no
immunoreactivity; 1, the representative staining intensity was weak;
2, intermediate; and 3, strong. The final estimation of immunor-
eactivity was assigned as follows: negative/faint, if the sum of
proportion score and intensity score ranged from 0 to 2; medium, if
the sum ranged from 3 to 5; and strong, if the sum ranged from 6 to 8.
We judged cases graded negative/faint as TUBB3 negative and those
graded medium or strong as TUBB3 positive.
Indirect immunofluorescence
For immunofluorescence staining, cells were seeded onto slide glass
(2.5 2.5 cm) and grown for appropriate periods. All cells were
gently washed with phosphate-buffered saline (PBS) and fixed in 4%
paraformaldehyde for 20minutes at room temperature. Cells were
permeabilized for 10minutes with 0.2% Triton X-100, followed by
blocking at room temperature for 30minutes in 5% BSA. After being
washed with PBS, cells were stained with primary antibody in a dark
chamber overnight at 4 1C. After a wash with PBS, cells were
incubated in secondary antibodies in a dark chamber for 2 hours
at 37 1C. After a further wash with PBS, cells were stained with
40,6-diamino-2-phenylindole in a dark chamber for 10minutes at
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room temperature. Cells were washed with PBS, mounted
and viewed by fluorescence microscopy (Axioplan 2, AxioCam
Hrc camera and Axiovision 4.5 software; all from Carl Zeiss,
Oberkochen, Germany).
Real-time quantitative PCR assay
For the real-time quantitative-PCR assay, primers and a fluorogenic
probe were designed with Primer Express software (ABI): TUBB3-
115F (GGG CCA AGT TCT GGG AAG TC), TUBB3-183R (AGT CGC
CCA CGT AGT TGC C) and the probe (TUBB3-140T, FAM-TGA
TGA GCA TGG CAT CCA TCG ACC CCA G-TAMRA). The forward
and reverse primer sequences for GAPDH were GAPDH mRNA F
(GAA GGT GAA GGT CGG AGT C) and GAPDH mRNA R (GAA
GAT GGT GAT GGG ATT TC), respectively. The hybridization
probe sequence was FAM-CAA GCT TCC CGT TCT CAG CC-
TAMURA. The RQ-reverse transcriptase-PCR assay was performed
with an ABI PRISM 7500 Sequence Detector (Applied Biosystems
(ABI), Foster City, CA). The reaction mixture contained 50 ng of
cDNA, 200 nmol l1 each primer, 2mM probe, and 25ml of TaqMan
Universal PCR Master Mix (ABI) in a final volume of 50 ml. The
cDNA was subjected to 50 cycles of a two-step PCR consisting of a
15-second denaturation step at 95 1C and a 1-minute combined
annealing/extension step at 60 1C. Relative expression levels of
mRNA were calculated by the DDCT method according to User
Bulletin no. 2 (ABI).
Western blot
All cell lines were cultured to 70–80% confluence on 10 cm Petri
dishes. Cold PBS (1ml) was added, and the cells were removed from
the dishes by scraping. After removal of the supernatants, the cell
pellet was dissolved in cell lysis buffer (50mM Tris-HCl, pH 8.0/
150mM NaCl/1mM EDTA, pH 8.0/1% Triton X-100/0.1% sodium
deoxycholate/0.1% SDS/1mM PMSF/10mM NaF/2mM Na3VO4/1
protease inhibitor Complete; Roche Diagnostics GmbH, Mannheim,
Germany). Cell samples containing equal amounts of protein were
mixed with 2 sample buffer and heated for 4minutes at 95 1C.
Protein was electrophoresed on 10% SDS–PAGE for 1.5 hours at
125V constant voltage, and then transferred onto polyvinylidene
difluoride membranes (Amersham Biosciences) for 1 h at 25V
constant voltage. Membranes were blocked with 5% blocking
reagent (Amersham Biosciences) in 1 Tris-buffered saline/Tween-
20 buffer for 1 h at room temperature and immunostained with
primary antibodies for overnight at 4 1C. Then, the membranes
were rinsed with Tris-buffered saline/Tween-20 and incubated
with horseradish peroxidase-conjugated secondary antibodies
(Amersham Biosciences) for 1 hour at room temperature. Signals
were detected with ECL Plus (Amersham Biosciences) and Chemi-
Doc XRS (Bio-Rad Laboratories, Hercules, CA). The intensity of the
detected signals was measured by 1D analysis software (Quantity
One; Bio-Rad). For normalization of the target, GAPDH was used as
an internal control.
Cell viability assay
Cells were seeded into 96-well cell culture plates at a density of
2.5 104 cells per well for 24 hours. To examine dose–response
relationships, one plate received an additional 5 ml per well of
paclitaxel (10, 20, 40, and 80 nM) for 72 hours at 37 1C. Another plate
received 40 nM paclitaxel for 24, 48, and 72hours to examine the
time dependency. Cell viability assays were performed with the Cell
titer-Glo Luminescent Cell Viability assay (Promega Co., Madison,
WI) according to the supplier’s instruction manual. Then, 100 ml of
buffer was added to each well and the plate was incubated for
10minutes at room temperature before measurement with a
luminometer (Centro LB960; Berthold Technologies, GmbH & Co.
KG, Bad Wildbad, Germany). At least eight samples were analyzed
for each experiment, and three independent experiments were
performed.
DNA laddering assay
DNA samples were extracted with a Puregene DNA Purification kit
(Gentra System Inc., Minneapolis, MN). The DNA (5 mg per well)
was applied to 2.0% agarose gel electrophoresis and visualized
under UV illumination by ethidium bromide staining.
Annexin V/propidium iodide flow cytometric analysis
To evaluate the differences in the apoptotic effects of paclitaxel
treatment among the cell lines, we performed flow cytometric
analysis using an Annexin-V-FITC kit II (BD Biosciences, San Jose,
CA) according to the manufacturer’s instructions. Briefly, 1 105
washed cells resuspended in 100ml of annexin V binding buffer were
simultaneously incubated with 5 ml of FITC-conjugated annexin V
and 2ml of propidium iodide for 15minutes at room temperature.
Before cytometric analysis, the cell suspension was supplemented
with 500 ml of annexin V binding buffer. Samples were then run on a
FACSCalibur flow cytometer (BD Biosciences) equipped with an
argon laser and filter configuration for FITC/propidium iodide dye
combination. Light scatter and fluorescence signals were subjected
to linear and logarithmic amplification, respectively. At least 10,000
events were acquired.
Detection of apoptosis by flow cytometric analysis
Cells were fixed with an Intra Prep kit (Beckman Coulter, Fullerton,
FL), and stained with primary antibody (cleaved caspase-3, diluted
1:200) and Zenon Alexa Fluor 488 Rabbit IgG Labeling Kit
(Invitrogen) overnight at 4 1C. Detection was performed using a
flow cytometer (FACSCalibur, BD Biosciences). At least 10,000
events were acquired.
Small-interfering RNA
Control siRNA duplex (Stealth RNAi negative universal control H1 no.
2) was purchased from Invitrogen. siRNA duplexes specific for TUBB3
were designed with the aid of RNAi designer (http://www.invitrogen.
com) and commissioned from Invitrogen. Cells were transfected with
100pmol (for 3.5-cm dishes) or 200pmol (for 6-cm dishes) of siRNA
duplexes using 3 and 6ml of Lipofectamine RNAi MAX (Invitrogen),
respectively. Three siRNA oligos were generated: si-1475 (CCG CCC
UCC UGC AGU AUU U dTdT), si-1004 (GCA AGA ACA GCA GCU
ACU U dTdT), and si-761 (CCG UCA ACA UGG UGC CCU U dTdT).
All experiments included appropriate controls: a Lipofectamine RNAi
MAX reagent-only control (mock-transfected) and a nonsilencing
siRNA (negative control).
5-Aza-dC or PBA treatments
To evaluate the effects of epigenetic modification on TUBB3 protein
expression, we treated melanoma cell lines and NHEM cells with a
demethylating agent (5-Aza-dC, 3 mM) or a HDAC inhibitor (PBA,
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3mM) as previously described (Izutsu et al., 2008). Cells were seeded
at 3 105 cells per 6 cm dish 24 hours before the treatment. 5-Aza-
dC was removed after 24 hours, whereas PBA was continuously
administered by replacing the medium containing PBA every
24 hours for 5 days. After treatment, cells were harvested and
subjected to western blot.
ChIP assay
Cells were grown to 80% confluence in a 10-cm dish, and the
medium was replaced with fresh medium just before cross-linking. A
similarly handled plate was prepared for cell counting. Formalde-
hyde (1% final concentration) was added directly to the medium to
cross-link protein and DNA, followed by incubation at 37 1C for
10minutes. The ChIP assay with anti-acetyl-histone-H3 and -H4
(both from Upstate Biotech), and anti-HDAC1 (clone 2E10; Upstate
Biotech) was performed with the Shearing-ChIP Kit (Diagenode,
Lie`ge, Belgium) and OneDay ChIP Kit (Diagenode) in accordance
with the manufacturer’s instructions. The RQ-PCR assay was used to
analyze ChIP DNA with the ABI Prism 7500 sequence detector (ABI).
Primers and fluorogenic probes for the TUBB3 and GAPDH
promoters were designed with Primer Express software (ABI):
TUBB3-313F (GCA CCA AGG ACA GCG CC), TUBB3-563R (GCA
ACA AGA GCC AAA CTC CAT C), TUBB3-313CProbe (FAM-CTG
GCC TCG AAC GCC GGG TT-TAMRA), GAPDH CF (50-CTA GTG
TCC TGC TGC CCA C-30), GAPDH CR (50-AGG TCT TGA GGC
CTG AGC TAC-30), GAPDH Cprobe (50-FAM-AGC GGT TTT ACG
GGC-TAMURA-30). The PCR conditions and reaction mixtures have
been described previously (Izutsu et al., 2008). IP/input¼ (DNA
immunoprecipitated with each antibody-nonspecific antibody con-
trol/input DNA-nonspecific antibody control). Values represent the
means±SE of three experiments from two independent ChIP assays.
Statistical analysis
Correlation between TUBB3 protein expression and clinicopatholo-
gical data were analyzed by Fisher’s exact test or Kruskal–Wallis test.
Spearman’s correlation coefficient by rank test was introduced to
assess relationships between cell viability and relative TUBB3
protein expression. All data are presented as means±SE. Data were
analyzed by Mann–Whitney U-test for nonparametric samples. To
correlate results for TUBB3 protein immunostaining with overall
survival in patients with malignant melanoma, Kaplan–Meier
survival analysis and log-rank test were performed. The level of
significance was considered to be Po0.05.
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fluorescence for TUBB3 mRNA/protein expressions in two melanoma
cell lines.
Figure S3. Induction of apoptosis by treatment with paclitaxel in melanoma
cell lines and primary cultures of NHEMs.
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